Spero Therapeutics, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Spero Therapeutics filed an 8-K on 2026-10-27 reporting Item 5.02 events concerning departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. The filing header references these items but the actual text content detailing specific counterparties, names, dollar amounts, dates, share counts, or the nature of changes is not provided in the accessible excerpts—only metadata and XBRL taxonomy files are shown.
Why this rating
No concrete facts disclosed in accessible text. Standard 8-K officer/compensation disclosure likely routine; cannot assess materiality without specifics on who left, who was hired, or compensation size relative to $160M market cap.
Extracted items
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.